$HIMS missed on earnings which is unfortunate but the speculative asymmetry catalyst is the July FDA advisory committee which could allow compounding pharmacies to do peptides I expect price to run up into that meeting

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.